论文部分内容阅读
目的:对贝美前列素滴眼液对比同类药物拉坦前列素进行预算影响的初步分析。方法:应用预算影响分析方法对贝美前列素滴眼液上市后未来5年的可能费用与对照药物对比,得出增量情况。结果:按10%市场占有率情况下,2种药物费用增量为-16000万元,从不同地区的预算影响分析贝美前列素的治疗成本要低于拉坦前列素,年费用相差在300～400万元。结论:按假定情况,贝美前列素引入医保目录后与拉坦前列素相比年节约药品费用在16000万元及以上;预测影响分析结果受不同地域社会发展状况、经济环境和医疗卫生状况影响,按不同地区分层进行预算影响分析是必要的。
OBJECTIVE: To analyze the budgetary influence of latanoprost on the same kind of drug by comparison with that of beiraprost eyedrops. Methods: Apply the budget impact analysis method to compare the possible costs of the following 5 years after the listing of beimaprofezin eye drops with the control drugs, to obtain the incremental situation. Results: According to the market share of 10%, the incremental cost of the two drugs was -160 million yuan. From the budget impact of different regions, the treatment cost of beraprost was lower than that of latanoprost, and the difference in annual costs was 300 ~ 400 million. CONCLUSIONS: According to the hypothetical situation, the cost of annual drug saving compared with latanoprost is more than 160 million yuan after the introduction of the list of health insurance for beimaprost and the results of the prediction of impact analysis are affected by the social development, economic environment and medical and health conditions in different regions It is necessary to analyze the impact of the budget by stratification in different regions.